Skip to main content
Premium Trial:

Request an Annual Quote

Biocius, BlueSky Partner to Offer Sirtuin Enzyme Preparations

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biocius Life Sciences and BlueSky Biotech today announced a collaboration to offer what they said is the industry's only sirtuin enzyme preparations that are fully validated in a label-free functional assay.

The collaboration builds on an existing relationship and "will significantly improve drug discovery efficiency of the SIRT [silent mating type information regulation homolog] class of epigenetic modulating enzymes," the companies said in a statement. SIRTs are being researched as potential therapeutics for several indications, they added.

Financial terms of the deal were not disclosed.

The two firms intend to launch a selectivity panel of sirtuins and histone deacetylases as part of the partnership. The first release, of SIRT1, has been linked to the regulation of multiple cellular processes, such as insulin signaling, apoptosis, and cancer, Biocius and BlueSky said. Additional releases of validated enzymes are anticipated during the coming months.

Based in Wakefield, Mass., Biocius provides mass spectrometry-based services and products primarily for drug-discovery purposes. The company was spun out of Biotrove after that firm was acquired by Life Technologies late last year.

BlueSky, based in Worcester, Mass., is a contract research organization and provides services for pharmaceutical R&D.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.